As of January 22, 2025, Entrada Therapeutics (TRDA) has a market cap of $0.47 billion USD. According to our data, Entrada Therapeutics is ranked No.6200 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.47 B |
-27.47%
|
Dec 31, 2024 | $0.65 B |
14.58%
|
Dec 29, 2023 | $0.56 B |
11.61%
|
Dec 30, 2022 | $0.51 B |
-21.03%
|
Dec 31, 2021 | $0.64 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Ionis Pharmaceuticals
IONS
|
$5.13 B |
-0.000 M
|
USA
|
Wave Life Sciences
WVE
|
$1.78 B |
0.000 M
|
Singapore
|
Alnylam Pharmaceuticals
ALNY
|
$34.38 B |
-0.000 M
|
USA
|
Moderna
MRNA
|
$14.82 B |
-0.000 M
|
USA
|
BioMarin Pharmaceutical
BMRN
|
$11.82 B |
0.000 M
|
USA
|
PTC Therapeutics
PTCT
|
$3.48 B |
-0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
Beam Therapeutics
BEAM
|
$2.19 B |
0.000 M
|
USA
|
Market Cap | = | TRDA Stock Price | * | TRDA Shares Outstanding |
= | $12.54 | * | 37.42 M | |
= | $0.47 B |